EU/3/18/2002

About

On 21 March 2018, orphan designation (EU/3/18/2002) was granted by the European Commission to Pharmadev Healthcare Ltd, Ireland, for ribavirin for the treatment of Crimean-Congo haemorrhagic fever.

Key facts

Active substance
Ribavirin
Disease / condition
Treatment of Crimean-Congo haemorrhagic fever
Date of decision
21/03/2018
Outcome
Positive
Orphan decision number
EU/3/18/2002

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Pharmadev Healthcare Ltd
9 Collaire Court
Callan
Co. Kilkenny
R95NH26
Ireland
Tel. +353 56 77 06 537
E-mail: jlbarnoux@pharmadevhealthcare.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating